Literature DB >> 10845276

Microsatellite instability markers in breast cancer: a review and study showing MSI was not detected at 'BAT 25' and 'BAT 26' microsatellite markers in early-onset breast cancer.

S P Siah1, D M Quinn, G D Bennett, G Casey, R L Flower, G Suthers, Z Rudzki.   

Abstract

Microsatellite markers may provide evidence of faulty DNA mismatch repair (MMR) via the detection of microsatellite instability (MSI). The choice of microsatellite markers may impact on the MSI detection rate. In hereditary non-polyposis colon cancer (HNPCC), several informative microsatellite markers have been recommended. Two of these, BAT 25 and BAT 26, are quasi-homozygous, enabling analysis of tumour DNA in the absence of paired normal DNA. Sixty-six breast cancer patients under 45 years of age at diagnosis were examined for MSI at BAT 25 and BAT 26. Tumour DNA was extracted from paraffin-embedded tissue. No MSI was detected at the BAT 25 or BAT 26 loci. An additional five microsatellite markers, known to be informative for HNPCC, were examined for MSI in these patients. Apparently-normal profiles were achieved. A tabulated survey of 306 microsatellite markers used to detect MSI in breast cancer revealed that only 35.5% of markers detected MSI at an average rate of 2.9%. The MSI detection rate at the specific HNPCC markers varied from 0% to 10% in breast cancer, with D175250 and TP53 being the HNPCC markers most suitable for analysis of breast cancer. The size of the microsatellite marker's repeat unit did not impact on MSI detection rates. Compiled data from large studies (n > 100) revealed D115988 as the marker with the highest MSI detection rate. Genomic instability pathways of carcinogenesis, characterised by MMR defects and MSI, appear to play a role in the genesis of some breast cancer types.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845276     DOI: 10.1023/a:1006315315060

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  Evaluation of reliability on STR typing at leukemic patients used for forensic purposes.

Authors:  G Filoglu; O Bulbul; G Rayimoglu; F E Yediay; T Zorlu; S Ongoren; H Altuncul
Journal:  Mol Biol Rep       Date:  2014-02-22       Impact factor: 2.316

Review 2.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

3.  Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry.

Authors:  Michael D Walsh; Daniel D Buchanan; Margaret C Cummings; Sally-Ann Pearson; Sven T Arnold; Mark Clendenning; Rhiannon Walters; Diane M McKeone; Amanda B Spurdle; John L Hopper; Mark A Jenkins; Kerry D Phillips; Graeme K Suthers; Jill George; Jack Goldblatt; Amanda Muir; Kathy Tucker; Elise Pelzer; Michael R Gattas; Sonja Woodall; Susan Parry; Finlay A Macrae; Robert W Haile; John A Baron; John D Potter; Loic Le Marchand; Bharati Bapat; Stephen N Thibodeau; Noralane M Lindor; Michael A McGuckin; Joanne P Young
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

4.  Microsatellite instability analysis of bilateral breast tumors suggests treatment-related origin of some contralateral malignancies.

Authors:  Ekatherina Sh Kuligina; Maxim Yu Grigoriev; Evgeny N Suspitsin; Konstantin G Buslov; Olga A Zaitseva; Olga S Yatsuk; Yulia R Lazareva; Alexandr V Togo; Evgeny N Imyanitov
Journal:  J Cancer Res Clin Oncol       Date:  2006-08-10       Impact factor: 4.553

5.  Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel.

Authors:  Susan Kupka; Birgit Haack; Marty Zdichavsky; Tanja Mlinar; Christine Kienzle; Thomas Bock; Reinhard Kandolf; Stefan-Martin Kroeber; Alfred Königsrainer
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-08       Impact factor: 4.553

6.  Familial breast and bowel cancer: does it exist?

Authors:  Rodney J Scott; Katie A Ashton
Journal:  Hered Cancer Clin Pract       Date:  2004-02-15       Impact factor: 2.857

7.  Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins.

Authors:  Michael D Walsh; Margaret C Cummings; Sally-Ann Pearson; Mark Clendenning; Rhiannon J Walters; Belinda Nagler; John L Hopper; Mark A Jenkins; Graeme K Suthers; Jack Goldblatt; Kathy Tucker; Michael R Gattas; Julie L Arnold; Susan Parry; Finlay A Macrae; Michael A McGuckin; Joanne P Young; Daniel D Buchanan
Journal:  Mod Pathol       Date:  2013-02-01       Impact factor: 7.842

8.  Breast cancer immunohistochemistry can be useful in triage of some HNPCC families.

Authors:  S Shanley; C Fung; J Milliken; J Leary; R Barnetson; M Schnitzler; J Kirk
Journal:  Fam Cancer       Date:  2009-01-04       Impact factor: 2.375

9.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.

Authors:  Leisha A Emens; Sylvia Adams; Ashley Cimino-Mathews; Mary L Disis; Margaret E Gatti-Mays; Alice Y Ho; Kevin Kalinsky; Heather L McArthur; Elizabeth A Mittendorf; Rita Nanda; David B Page; Hope S Rugo; Krista M Rubin; Hatem Soliman; Patricia A Spears; Sara M Tolaney; Jennifer K Litton
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

Review 10.  Mutations in normal breast tissue and breast tumours.

Authors:  I P Tomlinson
Journal:  Breast Cancer Res       Date:  2001-07-26       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.